AgomAb Therapeutics NV
http://www.agomab.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AgomAb Therapeutics NV
Andera Reflects On Revitalized Biotech Scene
After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.
Agomab Gets $100m In Fifth Largest European Venture Round This Year
But the cash will probably not be enough to prove its lead compound’s efficacy for a severe form of Crohn’s disease.
Taking A Bold Path To Improve Fibrosis Prognosis
Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.
Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong
Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Origo Biopharma S.L.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice